MedTrace Logo

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

NCT04628871 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2024-05-03

No results posted yet for this study

Summary

Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.

Conditions

  • Hemophilia B
  • Mucopolysaccharidosis I
  • Mucopolysaccharidosis II

Interventions

BIOLOGICAL

SB-318

No study drug is administered in this study. Subject who received SB-318 in a previous trial will be evaluated in this trial for long-term safety.

BIOLOGICAL

SB-913

No study drug is administered in this study. Subject who received SB-913 in a previous trial will be evaluated in this trial for long-term safety.

BIOLOGICAL

SB-FIX

No study drug is administered in this study. Subject who received SB-FIX in a previous trial will be evaluated in this trial for long-term safety.

Sponsors & Collaborators

  • Sangamo Therapeutics

    lead INDUSTRY

Principal Investigators

  • Medical Monitor, MD · Sangamo Therapeutics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-03
Primary Completion
2030-01-01
Completion
2030-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04628871 on ClinicalTrials.gov